Dust mite allergy patients

The efficacy of subcutaneous SIT has been clearly shown in a metaanalysis of 43 double-blind placebo-controlled trials in allergic rhinitis as well as another meta-analysis of 16 double-blind placebo-controlled studies in asthma patients [13]. The mean clinical improvement was 45% reduction in symptoms and medication compared with placebo in rhinitis and 40% in asthma patients, which exceeds the effects of drug therapy. A recent meta-analysis also confirmed that asthma responds favorably to SIT [14], However, recently it could also be demonstrated that SIT is effective in patients with house dust mite allergy, allergic rhinitis and asthma [15]. Immunotherapy in these patients not only reduced rhinitis and asthma symptoms as well as rescue medication, but also had an impact on bronchial hyperreactivity over the 3-year follow-up period. [Pg.124]

Riechelmann H, Essig A, Duetschle T, Rau A, Rothermel B, Weschta M Nasal carriage of Staphylococcus aureus in house dust mite allergic patients and healthy controls. Allergy 2005 60 1418-1423. [Pg.131]

Wang CR, Chen PC, Liu MF. Increased circulating CCR3+ type 2 helper T cells in house dust mite-sensitive Chinese patients with allergic diseases. Asian Pac J Allergy Immunol 2003 21(4) 205-210. [Pg.253]

Werfel T, Breuer K, Rueff F, Przybilla B, Worm M, Grewe M, Ruzicka T, Brehler R, Wolf H, Schnitker J, Kapp A Usefulness of specific immunotherapy in patients with atopic dermatitis and allergic sensitization to house dust mites a multicentre, randomized, dose-response study. Allergy 2006 61 202-205. [Pg.109]

Bussmann C, Maintz L, Hart J, Allam JP, Vrtala S, Chen KW, Bieber T, Thomas WR, Valenta R, Zuberbier T, Sager A, Novak N Clinical improvement and immunological changes in atopic dermatitis patients undergoing subcutaneous immunotherapy with a house dust mite allergoid a pilot study. Clin Exp Allergy 2007 37 1277-1285. [Pg.111]

Bousquet J, Scheinmann P, Guinnepain MT, Perrin-Fayolle M, Sauvaget J, Tonnel AB, Pauli G, Caillaud D, Dubost R, Leynadier F, Vervloet D, Herman D, Galvain S, Andre C Sublingual-swallow immunotherapy (SLIT) in patients with asthma due to house-dust mites A double blind placebo-controlled study. Allergy 1999 54/3 249-260. [Pg.8]

Scadding GK, Brostoff J Low dose sublingual therapy in patients with allergic rhinitis and asthma due to house dust mite. Clin Allergy 1986 16 483-491. [Pg.42]

Carefully selected patients with rhinitis, conjunctivitis and/or asthma caused by pollen, house dust mite or cat allergy. Immunotherapy is also indicated when asthma during the pollen season complicates rhinoconjunctivitis. [Pg.123]

Pichler CE, Helbling A, Pichler WJ Three years of specific immunotherapy with house-dust-mite extracts in patients with rhinitis and asthma Significant improvement of allergen-specific parameters and of nonspecific bronchial hyperreactivity. Allergy 2001 56 301-306. [Pg.125]

Cloosterman SG, SchermerTR, Bijl-Hofland ID, van derHS, Bmnekreef B, Van Den Elshout FJ, et al Effects of house dust mite avoidance measures on Der p 1 concentrations and clinical condition of mild adult house dust mite-allergic asthmatic patients, using no inhaled steroids. Clin Exp Allergy 1999 29 1336-1346. (Ib)... [Pg.149]

Gniber W, Eber E, Mileder P, et al Effect of specific immunotherapy with house dust mite extract on the bronchial responsiveness of paediatric asthma patients. Clin Exp Allergy 1999 29 176-781. (lb)... [Pg.150]

The effectiveness of immunotherapy for seasonal allergic rhinitis appears to be better than that seen with perennial rhinitis, in part because it is more difficult to determine which allergen is responsible for perennial symptoms, and it is more due to multiple sensitizations. Effectiveness has been shown in a number of clinical studies using a variety of pollen extracts, even in patients with severe disease resistant to pharmacotherapy." " Specific immunotherapy for house dust mites has had good results in appropriately selected patients, while several studies have described marked improvement in patients with allergy to cats. Data indicate that in some patients 3 years of immunotherapy may be sufficient to give lasting benefit." ... [Pg.1738]

Kniest FM, Young E, Van Praag MC, Vos H, Kort HS, Koers WJ, et al. Clinical evaluation of a double-bUnd dust-mite avoidance trial with mite-allergic rhinitic patients. Clin Exp Allergy 1991 21(l) 39-47. [Pg.263]

Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...